Lung cancer: Biology and treatment options

H Lemjabbar-Alaoui, OUI Hassan, YW Yang… - … et Biophysica Acta (BBA …, 2015 - Elsevier
Lung cancer remains the leading cause of cancer mortality in men and women in the US
and worldwide. About 90% of lung cancer cases are caused by smoking and the use of …

Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer

J Scheiermann, DM Klinman - Vaccine, 2014 - Elsevier
Synthetic oligonucleotides (ODN) that express unmethylated “CpG motifs” trigger cells that
express Toll-like receptor 9. In humans this includes plasmacytoid dendritic cells and B cells …

[HTML][HTML] Immunotherapy for colorectal cancer

S Koido, T Ohkusa, S Homma, Y Namiki… - World journal of …, 2013 - ncbi.nlm.nih.gov
The incidence of colorectal cancer (CRC) is on the rise, and the prognosis for patients with
recurrent or metastatic disease is extremely poor. Although chemotherapy and radiation …

Cancer immunotherapy: a future paradigm shift in the treatment of non–small cell lung cancer

VK Anagnostou, JR Brahmer - Clinical Cancer Research, 2015 - AACR
Emerging evidence on the role of the antitumor activity of the immune system has generated
great interest in immunotherapy even for tumors that were historically considered as …

The epidermal growth factor receptor and its inhibition in cancer therapy

JR Woodburn - Pharmacology & therapeutics, 1999 - Elsevier
Much effort has been expended in the search for inhibitors of signalling molecules that may
prove to be important therapeutically in cancer. The epidermal growth factor receptor …

The landscape of immunotherapy in advanced NSCLC: Driving beyond PD-1/PD-L1 inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, vaccines)

A De Giglio, A Di Federico, G Nuvola, C Deiana… - Current oncology …, 2021 - Springer
Abstract Purpose of Review In this review, we analyzed the current landscape of non-PD-(L)
1 targeting immunotherapy. Recent Findings The advent of immunotherapy has completely …

Why the epidermal growth factor receptor? The rationale for cancer therapy

J Baselga - The oncologist, 2002 - academic.oup.com
Abstract Learning Objectives After completing this course, the reader will be able to: Explain
the molecular biology of epidermal growth factor receptor (EGFR) function in malignant cells …

A phase III clinical trial of the epidermal growth factor vaccine CIMAvax-EGF as switch maintenance therapy in advanced non–small cell lung cancer patients

PC Rodriguez, X Popa, O Martínez, S Mendoza… - Clinical Cancer …, 2016 - AACR
Purpose: EGFR is a well-validated target for patients with non–small cell lung cancer
(NSCLC). CIMAvax-EGF is a therapeutic cancer vaccine composed of human recombinant …

Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans

ID Davis, W Chen, H Jackson… - Proceedings of the …, 2004 - National Acad Sciences
NY-ESO-1 is a “cancer-testis” antigen expressed in many cancers. ISCOMATRIX is a
saponin-based adjuvant that induces antibody and T cell responses. We performed a …

New frontiers in the treatment of colorectal cancer: Autophagy and the unfolded protein response as promising targets

P Mokarram, M Albokashy, M Zarghooni, MA Moosavi… - Autophagy, 2017 - Taylor & Francis
Colorectal cancer (CRC), despite numerous therapeutic and screening attempts, still
remains a major life-threatening malignancy. CRC etiology entails both genetic and …